iSpecimen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 259 out of 482 in the Software & IT Services industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
iSpecimen Inc's Score
Industry at a Glance
Industry Ranking
259 / 482
Overall Ranking
532 / 4521
Industry
Software & IT Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
iSpecimen Inc Highlights
StrengthsRisks
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.29M.
Overvalued
The company’s latest PE is -0.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 349.56K shares, increasing 39.04% quarter-over-quarter.
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.